Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Engcan77on Jan 18, 2023 11:24am
99 Views
Post# 35230674

RE:RE:RE:Q&A

RE:RE:RE:Q&AIt was nice to see a good turn out for the Q&A. I thought there was good questions asked. Thanks to those who stepped up and asked them. The webinar could have been set up for a bit longer this time around, because of years of questions that have gone unanswered.  Dr Beiber may have been a good addition this time around. Would have liked to hear his perspective on the company. What changes he would like to see. Seeing that nothing has come of his analysis so far (if ever)
Sounds like a company from China is interested in pet deal, and human use of their product for diabetes is still something this company could pursue.
Thought it was interesting to hear Howard say that it was up to the company that owned the rights to TFC-1067, had the option to use it for skin lightner and not just for dark spots, however was a sensitive market to get into.
Lots more in the pipeline with anti aging trials going on, and Anti-viral is a huge market. Lots to look forward to. It is very frustrating because everything moves at a snails pace. Howard said the companies they deal with are so knowledgeable that the info they want is very indepth before moving forward.

<< Previous
Bullboard Posts
Next >>